Yahoo España Búsqueda web

Search results

1. bmccancer.biomedcentral.com › articles › 10Immunotherapy combined with apatinib in the treatment of advanced...

   bmccancer.biomedcentral.com › articles › 10

   • En caché

   Hace 4 días · Gastric or gastroesophageal junction (G/GEJ) tumors are a common malignancy with a rather poor prognosis, which ranks as the fifth most common malignancy and the third leading cause of cancer deaths, and the majority of cases are diagnosed at an advanced stage [1, 2].With respect to advanced or metastatic G/GEJ adenocarcinomas that do not express HER2, fluoropyrimidine plus platinum-based ...

2. www.isct-cytotherapy.org › article › S1465-3249(24)00718-7State of the art and perspectives of CAR-T cell therapy for ...

   www.isct-cytotherapy.org › article › S1465-3249(24)00718-7

   Hace 4 días · Neuroblastoma is a solid, neuroendocrine pediatric solid tumor with divergent clinical behavior. Patients with high-risk disease have poor prognosis despite complex multimodal therapy, which requires the search for new therapeutic approaches. Chimeric antigen receptor T cells (CAR-T) have led to dramatic improvements in the survival of cancer patients, most notably those with hematologic ...

3. aacrjournals.org › clincancerres › articleFrom Rarity to Reality: Osimertinib's Promising Horizon in...

   aacrjournals.org › clincancerres › article

   • En caché

   Hace 1 día · Abstract. In the realm of advanced non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) therapy with tyrosine kinase inhibitors (TKIs), addressing optimal treatment for uncommon EGFR mutations like G719X in exon 18, S768I in exon 20, and L861Q in exon 21 remains a pivotal yet challenging frontier. Contrary to the well-established efficacy of EGFR-TKIs in common ...

4. Vídeos

   • 

     2:54:09

     youtube.com

     The Gerson Therapy - Charlotte Gerson on Cancer I College of Naturopathic Medicine

     11 dic 2012

     813.5K vistas

   • 

     2:17

     youtube.com

     Gerson Therapy for Cancer

     15 nov 2012

     49.3K vistas

   • 

     healnavigator.com

     What Is The Gerson Therapy For Cancer (2024)

     18 dic 2019

   Ver todo

5. www.cell.com › trends › pharmacological-sciencesDirections to overcome therapy resistance in cancer - Cell Press

   www.cell.com › trends › pharmacological-sciences

   Hace 5 días · Novel modalities for treatment of cancer have emerged because of advances in technology that have enabled expansion of our understanding of how cells transform to become cancerous and the role of the tumor microenvironment (TME). However, resistance to therapy poses a major problem for the successful treatment of cancer. Ongoing collaborative efforts of clinicians and researchers from ...

6. jamanetwork.com › journals › jamaoncologySystemic Anticancer Therapy and Overall Survival in Patients With...

   jamanetwork.com › journals › jamaoncology

   • En caché

   Hace 5 días · A total of 78 446 patients were included in the analysis : 4798 patients (6.1%) with urothelial cancer across 130 practices, 11 655 patients (14.9%) with breast cancer across 137 practices, 15 804 patients (20.1%) with colorectal cancer across 142 practices, 34 201 patients (43.6%) with NSCLC across 144 practices, 7368 patients (9.4%) with ...

7. www.esmoopen.com › issue › S2059-7029(24)X0009-5Table of Contents page: ESMO Open

   www.esmoopen.com › issue › S2059-7029(24)X0009-5

   Hace 4 días · Abstract Book of ESMO Breast Cancer 2024, Berlin, Germany, 15-17 May 2024. Open Access. ... A prospective randomized phase II trial investigating sequence of neoadjuvant chemotherapy and palbociclib/endocrine therapy for luminal breast cancer. A. Matikas, J. Bjöhle, E. Barnekow ... D. Shveid Gerson,... S.M. Tolaney, F. Lynce, D ...

8. www.astctjournal.org › article › S2666-6367(24)00407-XACT To Sustain: Adoptive Cell Therapy To Sustain access to non...

   www.astctjournal.org › article › S2666-6367(24)00407-X

   Hace 5 días · Genetically modified cell therapies (GMCT) can cure cancer and rare diseases after a single treatment course. Immune effector cells (IEC) such as chimeric receptor antigen (CAR) T cells represent a new paradigm in cancer care whereby a single infusion of CAR T cells can lead to durable remissions in patients with multiply relapsed B-cell hematologic malignancies.1-7 This approach has enormous ...